Clinical Trial Update: Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating safety, tolerability, and preliminary efficacy of escalating daily doses of topical LEO 43204 applied for two days to approximately 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LEO 43204

Snippet

Sponsor: LEO Pharma | Conditions: Actinic Keratosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-01-04